Tramadol

Dual mechanism of action combining weak mu-opioid receptor agonism and norepinephrine/serotonin reuptake inhibition characterizes tramadol, a Schedule IV synthetic opioid analgesic. Laboratory testing applications include pain management compliance monitoring, drugs of abuse screening, forensic toxicology investigations, postmortem toxicology, and clinical toxicology assessments, where tramadol and its active metabolite O-desmethyltramadol (M1) must be specifically targeted since they are not detected by standard opiate immunoassays. UTAK’s Pain Management, Pain Management Plus, and SAMHSA CONFIRM panels contain tramadol in lyophilized urine, whole blood, and oral fluid matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods. Stock and custom QC solutions can incorporate O-desmethyltramadol and related analytes such as tapentadol, oxycodone, hydrocodone, fentanyl, morphine, and other commonly monitored pain management drugs to address your laboratory’s comprehensive opioid and drugs of abuse testing requirements.